GH250117C37000
- 0.21
- 0.000.00%
Guardant Health Newsroom
Guardant Health Initiated at Overweight by Barclays
Barclays Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $60
Guardant Health Analyst Ratings
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
Guardant Health (GH) Receives a Buy From Craig-Hallum
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $39 to $55
Guardant Health's Strategic Milestones and Medicare Coverage Drive Buy Rating With $55 Price Target
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $42 to $42
Guardant Health (GH) Gets a Buy From Craig-Hallum
UBS Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $40
Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $45
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $34
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Scotiabank Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $47
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $34 to $60
Guardant Health (GH) Gets a Buy From Scotiabank
Guardant Health Price Target Raised to $50.00/Share From $48.00 by JP Morgan